167 related articles for article (PubMed ID: 22193644)
1. LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors.
Yin M; Lou C; Zhang W; Meng F; Zhang H; Ning X; Zhou R; Dong X; Lou G
Int J Gynecol Cancer; 2012 Jan; 22(1):54-62. PubMed ID: 22193644
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
[TBL] [Abstract][Full Text] [Related]
3. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.
Yang Y; Yang H; McNutt MA; Xiong F; Nie X; Li L; Zhou R
Oncol Rep; 2008 Nov; 20(5):1077-83. PubMed ID: 18949404
[TBL] [Abstract][Full Text] [Related]
4. Astrocyte elevated gene-1: a novel independent prognostic biomarker for metastatic ovarian tumors.
Li C; Chen K; Cai J; Shi QT; Li Y; Li L; Song H; Qiu H; Qin Y; Geng JS
Tumour Biol; 2014 Apr; 35(4):3079-85. PubMed ID: 24234336
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.
Li S; Wang L; Meng Y; Chang Y; Xu J; Zhang Q
Oncotarget; 2017 Jun; 8(25):41282-41293. PubMed ID: 28476037
[TBL] [Abstract][Full Text] [Related]
6. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
7. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis.
Yin M; Xu Y; Lou G; Hou Y; Meng F; Zhang H; Li C; Zhou R
Int J Cancer; 2011 Aug; 129(3):629-35. PubMed ID: 20857494
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
[TBL] [Abstract][Full Text] [Related]
9. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
10. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
Meng F; Tan S; Liu T; Song H; Lou G
Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
[TBL] [Abstract][Full Text] [Related]
12. Elevated lysosome-associated protein transmembrane-4β-35 is an independent prognostic marker in pancreatic carcinoma.
Zhang G; Liang Y; Huang Y; Chen Y; Zhou R
J Int Med Res; 2012; 40(4):1275-83. PubMed ID: 22971479
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma.
Kang Y; Yin M; Jiang W; Zhang H; Xia B; Xue Y; Huang Y
Am J Surg; 2012 Nov; 204(5):677-83. PubMed ID: 22578410
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.
Tang H; Tian H; Yue W; Li L; Li S; Gao C; Si L; Qi L; Lu M
Med Oncol; 2014 Jun; 31(6):974. PubMed ID: 24816841
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study.
Meng F; Luo C; Hu Y; Yin M; Lin M; Lou G; Zhou R
Int J Gynecol Pathol; 2010 Nov; 29(6):587-93. PubMed ID: 20881850
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer.
Li X; Song C; Wang K; Li N; Sun S; Li N; Zhao Z; Li M
Cancer Biomark; 2019; 25(1):19-27. PubMed ID: 31033460
[TBL] [Abstract][Full Text] [Related]
17. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.
Yang H; Xiong F; Qi R; Liu Z; Lin M; Rui J; Su J; Zhou R
J Surg Oncol; 2010 Apr; 101(5):363-9. PubMed ID: 20358632
[TBL] [Abstract][Full Text] [Related]
18. Relationship between LAPTM4B Gene Polymorphism and Prognosis of Patients following Tumor Resection for Colorectal and Esophageal Cancers.
Cheng X; Tian X; Wu X; Xing X; Du H; Zhou C; Zhang Q; Hao C; Wen X; Ji J
PLoS One; 2016; 11(7):e0158715. PubMed ID: 27391361
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
20. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.
Yang H; Lin M; Xiong F; Yang Y; Nie X; McNutt MA; Zhou R
Surg Today; 2011 Jun; 41(6):810-7. PubMed ID: 21626328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
